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In December 2019, a series of pneumonia of unknown cause emerged in Wuhan, China, which developed into a global 
pandemic with more than 200 million cases and 4 million deaths worldwide as of August 2021. The enveloped RNA 
betacoronavirus which was found to cause the pandemic was named severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2). Academia and industry started with non-clinical and clinical development of several SARS-CoV-2 
vaccine candidates immediately and results were achieved enormously fast. As an example, BioNTech and Pfizer got 
their joint SARS-CoV-2 vaccine approved less than eight months after trials started, while under normal circumstances 
vaccine development takes up to 10 – 15 years. In the case of the SARS-CoV-2 vaccine the extremely fast turnaround 
time from start of clinical trials to approval of the first vaccine candidates was driven by the urgent medical need and 
made possible by the mobilisation of enormous financial resources from the private and public sectors, as well as 
manpower and effort and the willingness of regulators to speed up timelines and approval processes. 
Looking at the extremely fast and successful development of several SARS-CoV-2 vaccine candidates, it is difficult to 
understand from a layman’s perspective why for others diseases like Human Immunodeficiency Virus/ Acquired 
Immunodeficiency Syndrome (HIV/AIDS) and tuberculosis (TB), which are among the top ten causes of death 
worldwide, development of effective vaccines takes so long. More than 30 years after HIV has been discovered, there is 
still no vaccine available for prevention of HIV infection. Development of several vaccine candidates has failed in clinical 
trials. The difficulties stem in large part from HIV’s unusual characteristics of replicating and mutating rapidly and high 
sequence diversity, its ability of immune system evasion and the creation of a persistent viral reservoir within the host. 
Development of the novel TB vaccine candidate VPM1002, which is designed to be a safe and effective vaccine for 
prevention of TB infection and TB recurrence, is an example of classical vaccine development. VPM1002 was invented 
in Germany, went through successful non-clinical development and is currently being tested in phase III clinical trial.  
The achievements during the last year fast development of SARS-CoV-2 vaccines during the last year have proven that 
in case of a pandemic situation and an urgent medical need, fast vaccine development is possible. The achievements were 
reached with high financial commitment and regulators have shown willingness and engagement to accelerate timelines 
for review and approval processes. It would be desirable if further vaccine developments could benefit from these efforts. 
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